Article 2 : SC Ruling on Stem Cell Use for Autism
Why in News: On 30 January 2026, the Supreme Court banned the use of stem cell therapy for autism outside approved clinical trials, setting a major precedent for healthcare regulation in India.
Key Details
- The Supreme Court held that stem cell therapy for autism lacks sufficient scientific evidence and cannot be offered as routine treatment.
- The Court relied on guidelines of ICMR and the National Medical Commission (NMC).
- It ruled that offering unproven therapy outside approved clinical trials constitutes professional misconduct.
- The judgment clarified that patients do not have the right to demand unproven therapies.
Scientific Background: Stem Cell Therapy
- What are Stem Cells? Stem cells are undifferentiated cells capable of self-renewal and differentiation into specialised cells. They exist in embryos and certain adult tissues.
- Approved Use in India: The only widely accepted and approved stem cell therapy is bone marrow transplantation for blood cancers and disorders. It is recognised by ICMR and global regulators.
- Experimental Nature in Other Diseases: Stem cells are being researched for neurological conditions like Parkinson’s disease, spinal cord injuries, and Alzheimer’s. However, most applications remain experimental.
- Risk Factors: Reported side effects include infection, seizures, immune reactions, and tumour formation. Therefore, strict clinical trials are mandatory before public use.
Autism and Misuse of Experimental Therapy
- Nature of Autism: Autism Spectrum Disorder (ASD) is a neurodevelopmental condition marked by communication deficits and repetitive behaviour. It is managed through behavioural and supportive therapy.
- Lack of Scientific Evidence: Clinical trials on stem cell use for autism have shown inconclusive or negative results due to poor methodology and short follow-up periods.
- Commercial Exploitation: Several private centres in India advertised “stem cell cures” for autism, charging lakhs of rupees per injection without proven benefit.
- Medical Tourism Concern: India emerged as a hub for stem cell medical tourism, despite regulatory guidelines restricting such use.
Regulatory Framework in India
- ICMR Guidelines (National Guidelines for Stem Cell Research): These guidelines classify stem cell therapy (except bone marrow transplant) as investigational and restrict use to approved clinical trials.
- National Medical Commission (NMC): The Ethics and Medical Registration Board declared promotion or advertisement of stem cell therapy for autism as professional misconduct.
- Drugs and Cosmetics Act, 1940: Regulates approval of new drugs and clinical trials in India.
- Role of Clinical Trial Regulation: Clinical trials must follow internationally accepted standards such as randomised controlled trials (RCTs) to ensure safety and efficacy.
Key Observations of the Supreme Court
- Ban on Routine Use: The Court ruled that stem cell therapy cannot be offered as routine treatment for autism due to lack of scientific backing.
- Clinical Trial Restriction: Any use must be within an approved and monitored clinical trial framework.
- No Right to Unproven Treatment: Patients cannot claim access to therapies that are scientifically unverified, even if they give consent.
- Professional Accountability: Doctors offering such therapy may face cancellation of registration and penalties.
Ethical and Governance Dimensions
- Right to Health (Article 21): The judgment balances the right to health with the need for evidence-based medicine.
- Informed Consent vs. Exploitation: Consent cannot justify unscientific and potentially harmful treatment.
- Predatory Commercialisation: Weak regulation allowed profit-driven healthcare practices, undermining medical ethics.
- Role of Civil Society: NGOs, caregivers, and medical professionals jointly petitioned the Court, demonstrating participatory governance.
Broader Implications for Healthcare Regulation
- Precedent for Emerging Therapies: The ruling may influence regulation of gene therapy, immunotherapy, and other advanced biomedical technologies.
- Strengthening Regulatory Bodies: Emphasises the need for stronger enforcement by ICMR, NMC, and drug regulators.
- Science-Based Policy Making: Reinforces the principle that healthcare decisions must rely on robust scientific evidence.
- Public Trust in Healthcare: Protects vulnerable patients from misinformation and financial exploitation.
Conclusion
India faces a dual challenge: ensuring access to innovative therapies while protecting citizens from unproven and exploitative treatments. The Supreme Court judgment sets a critical benchmark for evidence-based medicine and ethical healthcare governance. Strengthening regulatory enforcement, improving scientific literacy, and enhancing transparency in clinical research are essential to ensure that medical innovation benefits society without compromising safety and ethics.
EXPECTED QUESTION FOR UPSC CSE
Prelims MCQ
Q. With reference to stem cell therapy in India, consider the following statements:
- All forms of stem cell therapy are approved for clinical use in India.
- Bone marrow transplantation is a recognised stem cell therapy.
- The ICMR issues guidelines on stem cell research.
Which of the statements given above is/are correct?
(a) 1 and 2 only
(b) 2 and 3 only
(c) 1 and 3 only
(d) 1, 2 and 3
Answer: b